An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy
Translational Research · 2024
DOI: 10.1016/j.trsl.2024.07.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2024. Verfasst von Hirotaka Kawakami und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagosh…. Hauptthemen laut MEDLINE: Promoter Regions, Genetic, Transgenes, Oncolytic Virotherapy, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
In general, ensuring safety is the top priority of a new modality. Although oncolytic virus armed with an immune stimulatory transgene (OVI) showed some promise, the strategic concept of simultaneously achieving maximum effectiveness and minimizing side effects has not been fully explored. We generated a variety of survivin-responsive "conditionally replicating adenoviruses that can target and treat cancer cells with multiple factors (m-CRAs)" (Surv.m-CRAs) armed with the granulocyte-macrophage colony-stimulating factor (GM-CSF) transgene downstream of various promoters using our m-CRA platform technology. We carefully analyzed both therapeutic and adverse effects of them in the in vivo syngeneic Syrian hamster cancer models. Surprisingly, an intratumor injection of a conventional OVI, which expresses the GM-CSF gene under the constitutively and strongly active "cytomegalovirus enhancer and β-actin promoter", provoked systemic and lethal GM-CSF circulation and shortened overall survival (OS). In contrast, a new conceptual type of OVI, which expressed GM-CSF under the cancer-predominant and mildly active E2F promoter or the moderately active "Rous sarcoma virus long terminal repeat", not only abolished lethal adverse events but also prolonged OS and systemic anti-cancer immunity. Our study revealed a novel concept that optimal expression levels of an immune stimulatory transgene regulated by a suitable upstream promoter is crucial for achieving high safety and maximal therapeutic effects simultaneously in OVI therapy. These results pave the way for successful development of the next-generation OVI and alert researchers about possible problems with ongoing clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Department of Orthopaedic Surgery, Kagoshima Univ…
- Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
- Center for Innovative Therapy Research and Application, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
- Department of Orthopaedic Surgery, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Center for Innovative Therapy Research and Application, Kagoshima University Graduate School of Medical and Dental…
- Department of Gene Therapy and Regenerative Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan; Center for Innovative Therapy Research and Applic…
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
Zitieren
APA
Kawakami, H., Ijichi, N., Obama, Y., Matsuda, E., Mitsui, K., Nishikawaji, Y., Watanabe, M., Nagano, S., Taniguchi, N., Komiya, S., & Kosai, K. I. (2024). An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy. Translational Research. https://doi.org/10.1016/j.trsl.2024.07.002
Vancouver
Kawakami H, Ijichi N, Obama Y, Matsuda E, Mitsui K, Nishikawaji Y, et al. An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy. Translational Research. 2024. doi:10.1016/j.trsl.2024.07.002
BibTeX
@article{Kawakami2024,
author = {Kawakami, Hirotaka and Ijichi, Nobuhiro and Obama, Yuki and Matsuda, Eriko and Mitsui, Kaoru and Nishikawaji, Yuya and Watanabe, Maki and Nagano, Satoshi and Taniguchi, Noboru and Komiya, Setsuro and Kosai, Ken-Ichiro},
title = {An optimal promoter regulating cytokine transgene expression is crucial for safe and effective oncolytic virus immunotherapy},
journal = {Translational Research},
year = {2024},
doi = {10.1016/j.trsl.2024.07.002}
}
EUVIMED